Moxifloxacine Krka (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, the drug halts bacterial cell division, leading to bacterial death and clearance of the infection.

The specific dose of Moxifloxacine Krka is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function and local treatment guidelines. Healthcare providers select an appropriate regimen and duration for each individual case.

Safety data for moxifloxacin in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Pregnant or nursing women should discuss treatment options with their healthcare professional.

To order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxifloxacin offers a broad spectrum of activity against both Gram‑positive and Gram‑negative organisms, including atypical pathogens, and has a once‑daily dosing schedule for many infections. Compared with older fluoroquinolones, it may have a lower risk of certain resistance patterns but shares class‑related safety considerations such as tendon toxicity and QT prolongation.

Store the tablets at room temperature, below 25 °C (77 °F). Keep them in the original container, protect from moisture, heat and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Moxifloxacine Krka is taken orally as a whole tablet with a glass of water. It may be taken with or without food, but patients should follow any specific instructions from their prescriber. The tablet should be swallowed whole and not chewed or crushed.

Serious risks include tendon rupture or inflammation, especially in older adults or those on corticosteroids; QT interval prolongation that can lead to cardiac arrhythmias; severe allergic reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; and rare cases of hepatic dysfunction or peripheral neuropathy.

Patients with a known hypersensitivity to moxifloxacin or any fluoroquinolone should avoid the drug. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients taking medications that strongly interact with moxifloxacin without appropriate monitoring.